Furthermore, the EGFR signaling is required to initiate the KRAS oncogene-driven PanIN lesions and PDAC [63], and may be the possible reason that erlotinib exerts therapeutic effects for patients with pancreatic cancer. This evidence concerns the gene EGFR and familial pancreatic carcinoma.